For research and educational purposes only. Not medical advice.
GHRP-2 Reference
Educational, not medical advice reference for GHRP-2: GH Release; regulatory status, evidence posture, source review, and schedule notes. Also k…
Reference summary
Clinical data exist primarily as GH-release provocative testing in adult and pediatric populations, supporting its Japanese diagnostic approval. Long-term therapeutic outcome data are limited.
Regulatory and posture
- Categories
- GH Release
- Aliases
- Pralmorelin, KP-102, GHRP2
- Evidence posture
- human - Approved only as a diagnostic in Japan; no US therapeutic approval. Long-term outcome data are limited.
- Regulatory status
- GHRP-2 (pralmorelin) is approved in Japan only as a diagnostic agent for GH deficiency. There is no FDA-approved GHRP-2 drug label in the US. FDA lists GHRP-2 among bulk drug substances with safety-risk concerns for compounding.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed: Laferrère 2005 GHRP-2 increases food intake in healthy men (J Clin Endocrinol Metab)
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.